Institutional investors purchased a net $2.0 million shares of REGN during the quarter ended June 2019. This may signal that the smart money is gaining interest in this company as the 69.75% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
LYXOR INTERNATIONAL ASSET MANAGE... Bought 10.3 Thousand shares of Regeneron Pharmaceuticals...